Featured Publications
A randomized, double-blind, controlled trial to assess the effects of lactoferrin at two doses vs. active control on immunological and safety parameters in healthy adults
Ross D Peterson, Liana L Guarneiri, Caryn G Adams, Meredith L Wilcox, Anthony J Clark, Nathan P Rudemiller, Kevin C Maki, Carrie-Anne Malinczak
Recombinant human lactoferrin (rhLF) is of commercial interest for immune support as a food ingredient. The objective was to evaluate the immunogenicity/alloimmunization potential of Helaina rhLF (effera™) from K. phaffii over a 28-day period compared to bovine LF (bLF). Study 1 was a randomized, double-blind, parallel arm, controlled trial where 66 healthy adults were randomly allocated to 1 of 3 groups: high-dose rhLF (3.4 g/d), low-dose rhLF (0.34 g/d), or bLF (3.4 g/d). Participants completed a 28-day supplementation period with follow-up visits on Days 28, 56, and 84. Study 2 was a 12-week observational study with no intervention that enrolled 24 healthy adults.
Comparison of the effects of a phospholipid-enhanced fish oil versus krill oil product on plasma levels of eicosapentaenoic and docosahexaenoic acids after acute administration
Liana L Guarneiri, Meredith L Wilcox, Kevin C Maki
This randomized, double-blind, crossover study evaluated the bioavailability of eicosapentaenoic and docosahexaenoic acids (EPA+DHA) in a phospholipid-enhanced fish oil (PEFO) product versus a krill oil (KO) product (337 versus 206 mg EPA+DHA/1 g capsule) in healthy adults (N = 24). The aim of this study was to assess the plasma levels of EPA, DHA, and EPA+DHA following a single capsule of PEFO versus KO products in healthy adult men and women.
Investigation of the Influence of a Bitter Melon Product on Indicators of Cardiometabolic Health in Adults with Prediabetes
Liana L Guarneiri, Meredith L Wilcox, Chen-Meng Kuan, Kevin C Maki
The purpose of this study was to assess the impact of bitter melon extract supplementation on glycemia in individuals with prediabetes.